TRAP Activators
TRAP (Tartrate-Resistant Acid Phosphatase) activators constitute a diverse array of compounds intricately involved in modulating the enzymatic activity of TRAP, a pivotal enzyme expressed in osteoclasts that plays a central role in bone resorption and skeletal remodeling. Direct activators, such as GW0742, 1,25-Dihydroxyvitamin D3, WY-14643, and Calcitriol, exert their effects through direct interactions with specific receptors, influencing TRAP and contributing to the intricate regulation of bone metabolism. GW0742 and WY-14643 function as agonists for peroxisome proliferator-activated receptors (PPARs), initiating a cascade that leads to the transcriptional activation of TRAP, thereby promoting osteoclast differentiation. 1,25-Dihydroxyvitamin D3 and Calcitriol activate TRAP by binding to the vitamin D receptor (VDR), orchestrating gene expression crucial for bone remodeling.
Indirect activators, including Forskolin, PGE2, Zoledronic Acid, and PTH (1-34), modulate TRAP activity through intricate signaling pathways. Forskolin, by elevating cAMP levels, activates PKA, thereby impacting TRAP expression and contributing to the regulatory processes governing osteoclast differentiation. PGE2, acting through EP2 and EP4 receptors, stimulates cAMP/PKA signaling, indirectly influencing TRAP activity and bone resorption. Zoledronic Acid, by inhibiting FPPS, perturbs prenylation processes and osteoclast activity, potentially impacting TRAP expression within the context of skeletal remodeling. PTH (1-34) activates PKA through elevated cAMP, thereby intricately regulating TRAP and contributing to the orchestration of bone metabolism. Additional compounds, including RANKL (Recombinant), Tauroursodeoxycholic Acid (TUDCA), Epigallocatechin Gallate (EGCG), and Quercetin, exert their effects indirectly by targeting specific cellular processes. RANKL (Recombinant) directly engages RANK on osteoclast precursors, initiating signaling cascades that culminate in TRAP activation and subsequent bone resorption. TUDCA mitigates endoplasmic reticulum (ER) stress-related pathways, potentially influencing TRAP expression and osteoclast differentiation. EGCG interferes with RANKL signaling, impacting TRAP activation and contributing to bone health. Quercetin, through the suppression of inflammatory pathways, holds the potential to influence TRAP and modulate the intricate processes of skeletal remodeling.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW 0742 | 317318-84-6 | sc-203991 sc-203991A | 10 mg 50 mg | $194.00 $831.00 | 11 | |
GW0742 directly activates TRAP by acting as a PPAR-β/δ agonist. It binds to PPAR-β/δ receptors, leading to transcriptional activation of TRAP. This interaction enhances osteoclast differentiation and activity, promoting bone remodeling and influencing the cellular processes involved in bone metabolism. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin indirectly activates TRAP by elevating cAMP levels. It activates adenylate cyclase, increasing cAMP production, which activates PKA. PKA then influences TRAP expression, impacting osteoclast differentiation and bone resorption. This modulation contributes to the regulation of bone homeostasis and the processes involved in skeletal remodeling. | ||||||
1α,25-Dihydroxyvitamin D3 | 32222-06-3 | sc-202877B sc-202877A sc-202877C sc-202877D sc-202877 | 50 µg 1 mg 5 mg 10 mg 100 µg | $220.00 $645.00 $1000.00 $1500.00 $440.00 | 32 | |
1,25-Dihydroxyvitamin D3 directly activates TRAP by binding to the vitamin D receptor (VDR). The VDR complex regulates TRAP expression, influencing osteoclast differentiation and bone resorption. This activation plays a crucial role in maintaining bone homeostasis and the processes involved in skeletal development and remodeling. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 indirectly activates TRAP by binding to EP2 and EP4 receptors, elevating cAMP levels. This activates PKA, which influences TRAP expression, impacting osteoclast differentiation and bone resorption. PGE2-mediated TRAP activation is a crucial signaling pathway in bone metabolism and skeletal remodeling processes. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic Acid indirectly activates TRAP by inhibiting farnesyl pyrophosphate synthase (FPPS), leading to reduced prenylation of small GTPases. This influences osteoclast activity, potentially affecting TRAP expression and bone resorption. Zoledronic Acid's impact on TRAP activation contributes to its role in modulating bone turnover and skeletal health. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
WY-14643 directly activates TRAP by acting as a PPAR-α agonist. It binds to PPAR-α receptors, leading to transcriptional activation of TRAP. This interaction enhances osteoclast differentiation and activity, influencing bone remodeling and cellular processes involved in bone metabolism. | ||||||
Parathyroid hormone fragment (1-34) | 52232-67-4 | sc-487943 | 100 µg | $185.00 | ||
PTH (1-34) indirectly activates TRAP by binding to PTH receptors, elevating cAMP levels. This activates PKA, which influences TRAP expression and osteoclast differentiation. PTH-mediated TRAP activation is a crucial regulatory mechanism in bone metabolism and skeletal remodeling processes. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG indirectly activates TRAP by inhibiting the RANKL signaling pathway. It interferes with RANKL-RANK interaction, potentially influencing TRAP expression and osteoclast differentiation. EGCG's impact on TRAP activation contributes to its potential role in modulating bone health and the processes involved in skeletal remodeling. | ||||||
Tauroursodeoxycholic Acid, Sodium Salt | 14605-22-2 | sc-281165 | 1 g | $644.00 | 5 | |
TUDCA indirectly activates TRAP by inhibiting ER stress-related pathways. It mitigates unfolded protein response (UPR), potentially influencing TRAP expression and osteoclast differentiation. TUDCA's impact on TRAP activation contributes to its potential role in regulating bone homeostasis and the processes involved in skeletal remodeling. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin indirectly activates TRAP by inhibiting inflammatory pathways. It suppresses NF-κB activation, potentially influencing TRAP expression and osteoclast differentiation. Quercetin's impact on TRAP activation contributes to its potential role in modulating bone health and the processes involved in skeletal remodeling. | ||||||